Genzyme Corp. (Nasdaq: GENZ) announced the withdrawal of the European application to extend the Evoltra® (clofarabine) product label to include the treatment of elderly patients with acute myeloid leukemia (AML). This application and the data on which it was based were filed by Bioenvision, Ltd. before the company was acquired by Genzyme last year.
Discuss Add this link to...Bury Add to:
| Bookmarks
Comments